Adaptive biotechnologies corporation (ADPT)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19
Operating activities
Net loss

-31,403

-20,611

-13,950

-15,659

-18,386

Adjustments to reconcile net loss to net cash (used in) provided by operating activities:
Depreciation expense

1,554

1,654

1,635

1,447

1,364

Noncash lease expense

631

-

-

-

-

Share-based compensation expense

4,675

3,411

3,335

3,332

3,046

Intangible assets amortization

424

428

428

423

419

Investment amortization

556

930

1,637

1,278

618

Fair value adjustment of convertible preferred stock warrant

-

0

0

2,248

18

Benefit from income tax

-300

-

-

-

-

Other

-114

-

-

-

-

Changes in operating assets and liabilities:
Accounts receivable, net

-3,278

3,419

1,953

3,186

-741

Inventory

1,449

402

663

149

17

Prepaid expenses and other current assets

-3,526

1,736

5,957

-2,849

3,732

Accounts payable and accrued liabilities

-4,603

3,018

1,817

1,691

-377

Deferred rent

-

706

-148

-245

-235

Operating lease liabilities

-333

-

-

-

-

Deferred revenue

-6,926

-9,282

-12,505

-7,366

296,080

Other

215

-

-

-

-

Net cash (used in) provided by operating activities

-31,606

-26,791

-30,138

-15,970

278,303

Investing activities
Purchases of property and equipment

2,963

2,416

3,430

1,523

3,831

Purchases of marketable securities

107,747

112,124

413,422

87,811

270,860

Proceeds from sales and maturities of marketable securities

253,469

161,220

156,000

43,985

52,515

Net cash provided by (used in) investing activities

142,759

46,680

-260,852

-45,349

-222,176

Financing activities
Proceeds from exercise of stock options

5,000

1,748

318

1,859

130

Other

-

-2

-1

-3

-6

Net cash provided by financing activities

4,959

1,746

319,550

-1,504

124

Net increase in cash, cash equivalents and restricted cash

116,112

21,635

28,560

-62,823

56,251

Noncash investing and financing activities
Purchases of equipment included in accounts payable and accrued liabilities

627

275

-992

1,067

423

Deferred offering costs included in accounts payable and accrued expenses

-

-

-

-392

1,825

Derecognition of lease financing arrangements upon adoption of guidance on accounting for leases

36,607

-

-

-

-